Cargando…

Weight loss efficiency and safety of tirzepatide: A Systematic review

OBJECTIVE: Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy and safety of tirzepatide for weight loss in type 2 diabetes mellitus (T2D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Fei, Yu, Bin, Ling, Baodong, Lv, Guangyao, Shang, Huijun, Zhao, Xia, Jie, Xiaoling, Chen, Jing, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159347/ https://www.ncbi.nlm.nih.gov/pubmed/37141329 http://dx.doi.org/10.1371/journal.pone.0285197

Ejemplares similares

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
por: Tang, Yan, et al.
Publicado: (2022)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives
por: Arunachalam, Amar, et al.
Publicado: (2023)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
por: Sinha, Rachel, et al.
Publicado: (2023)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
por: Meng, Zhuqing, et al.
Publicado: (2023)

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
por: Karrar, Hani Raka, et al.
Publicado: (2023)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
por: Zeng, Qingyue, et al.
Publicado: (2023)

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis
por: Guan, Ruifang, et al.
Publicado: (2022)

Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
por: Boye, Kristina S., et al.
Publicado: (2023)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
por: Viljoen, Adie, et al.
Publicado: (2023)

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
por: Bhagavathula, Akshaya Srikanth, et al.
Publicado: (2021)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
por: El, Kimberley, et al.
Publicado: (2023)

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
por: Heise, Tim, et al.
Publicado: (2023)

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
por: Rohani, Pejman, et al.
Publicado: (2023)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
por: Sattar, Naveed, et al.
Publicado: (2022)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide
por: Wang, Jingyao, et al.
Publicado: (2022)

FRI483 Changes In Thyroid Function Test With Tirzepatide Use In Patients With Hypothyroidism
por: Kaylee Yu, Gayoung, et al.
Publicado: (2023)

Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis
por: Yu, Bin, et al.
Publicado: (2022)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
por: Zhou, Qian, et al.
Publicado: (2023)

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2
por: Benneyworth, Brian D, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1n181vfqkd02scs33ps92kuef6